Article Text
PDFCommentary
‘Green’ bioethics widens the scope of eligible values and overrides patient demand: comment on Parker
Statistics from Altmetric.com
Footnotes
Twitter @AndersHerlitz, @erik_malmqvist, @christianmunthe
AH, EM and CM contributed equally.
Funding This research was supported by the UGOT Challenges Initiative at the University of Gothenburg, no award/grant number, for CARe: The Centre for Antibiotic Resistance Research; the Swedish Research Council (VR), contract no. 2018-05771, for the project EDAR: The Environment as a Driver for Antibiotic Resistance; and the Swedish Innovation Agency VINNOVA, contract no. 2021-02699, for the project PLATINEA 2.0: Availability and Individualised Use of Antibiotics.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Barriers to green inhaler prescribing: ethical issues in environmentally sustainable clinical practice
- Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment
- Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England
- Inhaler devices for asthma
- Reducing carbon footprint of inhalers: analysis of climate and clinical implications of different scenarios in five European countries
- Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma
- Challenges in changing to non-chlorofluorocarbon inhalers in the treatment of asthma
- P229 Factors affecting inhaler choice and adherence in urban Liverpool
- Carbon footprint impact of the choice of inhalers for asthma and COPD
- The scope of patient, healthcare professional and healthcare systems responsibilities to reduce the carbon footprint of inhalers: a response to commentaries